Medical/Pharmaceuticals
Lung Scan Technology Reveals Hidden Secrets of Airway Disease
Scientists Unveil 4DMedical Imaging Breakthrough that Spots Early Lung Disease Missed by Standard Tests LOS ANGELES, July 15, 2025 /PRNewswire/ -- Researchers at Vanderbilt University, Johns Hopkins University, University of Miami, and The Alfred Hospital studied the lungs of subjects including ...
2025-07-15 19:07
1669
Argon Medical Streamlines Distribution of Product and Enhances Customer Training for Europe, Asia, and Africa with the Debut of a Modern, Mixed-Use Facility
PLANO, Texas, July 15, 2025 /PRNewswire/ -- Argon Medical, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announces the grand opening of its new Distribution & Education Center (ADEC), strategicall...
2025-07-15 17:12
1687
AXA and China Biotech Services Sign Memorandum of Understanding
Joint effort to explore innovative cancer treatment solutions and broaden options for customers HONG KONG, July 15, 2025 /PRNewswire/ -- AXA China Region Insurance Company (Bermuda) Limited, together with AXA International Reinsurance (Shanghai) Company Limited ("AXA"), is pleased to announce th...
2025-07-15 15:23
2117
Baraya Extended Care Closes Series B Funding Round Bringing Total Capital Raised to USD 124 Million from TVM Capital Healthcare and a Syndicate of Prominent Investors
TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and RIYADH, Saudi Arabia, July 15, 2025 /PRNewswire/ -- TVM Capital Healthcare announces the closing of a Ser...
2025-07-15 14:00
1705
Baraya Extended Care Closes Series B Funding Round Bringing Total Capital Raised to USD 124 Million from TVM Capital Healthcare and a Syndicate of Prominent Investors
TVM Capital Healthcare's oversubscribed fundraise for Baraya Extended Care addresses critical gaps in long-term care, supporting Saudi Arabia's Vision 2030 healthcare goals. DUBAI, UAE and RIYADH, Saudi Arabia, July 15, 2025 /PRNewswire/ -- TVM Capital Healthcare announces the closing of a Ser...
2025-07-15 14:00
1564
Divamics' AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners
SUZHOU, China, July 15, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of B...
2025-07-15 07:31
1701
Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, onc...
2025-07-15 07:00
2018
Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma
BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the s...
2025-07-15 04:05
1891
LABCONNECT APPOINTS MITCHELL BLUMENFELD AS CHIEF FINANCIAL OFFICER
JOHNSON CITY, Tenn., July 15, 2025 /PRNewswire/ -- LabConnect is pleased to announce the appointment of Mitch Blumenfeld as its Chief Financial Officer, effective August 4, 2025. Mitch joins LabConnect with proven experience as Chief Financial Officer for high-growth companies in multiple industr...
2025-07-15 02:56
1784
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
* Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model * Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth * Creates a combined company with ...
2025-07-14 19:00
2475
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
* Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D * Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14,...
2025-07-14 15:38
1462
Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU, Finland, July 14, 2025 /PRNewswire/ -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generati...
2025-07-14 15:00
1593
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
* Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) * 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1b trial of azer-cel, an allogeneic off-the-shelf CD19 CAR T therapy in relapsed diffuse l...
2025-07-14 12:43
1594
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP34...
2025-07-14 08:00
1639
Bio Investments Group (BIG) and International Vaccine Institute (IVI) Forge Partnership to Accelerate Vaccine Self-Reliance in Africa and the Middle East
ZUG, Switzerland and SEOUL, July 11, 2025 /PRNewswire/ -- The Bio Investments Group AG (BIG), a leading global healthcare-technology transfer platform, and the International Vaccine Institute (IVI), an international organization dedicated to advancing vaccine discovery, development, and delivery,...
2025-07-11 23:08
3692
Australian Dentists Endorse Smartee's Mandibular Repositioning Technology at Global Symposium in Kunming
Clinicians praise the S8-SGTB appliance for accelerating outcomes, improving patient satisfaction, and offering a non-invasive solution for Class II malocclusions. KUNMING, China, July 11, 2025 /PRNewswire/ -- Smartee Denti-Technology recently welcomed orthodontic experts and partners from Austr...
2025-07-11 17:38
2834
Dräger Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Respiratory Devices Innovation
Dräger recognized for pioneering innovations in respiratory care, delivering measurable improvements in patient outcomes, clinical efficiency, cost-effectiveness and critical care training SAN ANTONIO, July 10, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce thatDräger has received...
2025-07-10 21:00
2043
LG Debuts Next-Generation Precision Medical AI
Joint Development Underway: World-Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 /PRNewswire/ -- LG AI Research announced on July 9 the official launch of 'EXAONE Path 2.0', its next-generation precision medical AI model. Followin...
2025-07-10 20:54
2382
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
MIDDLETOWN, Del., July 10, 2025 /PRNewswire/ -- Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics,...
2025-07-10 19:00
1690
Vita Therapeutics and I Peace announced a development program to generate iPS-derived differentiated cells for transplant therapy with an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells
PALO ALTO, Calif., July 10, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace,
Inc. (https://ipeace.com/en/
2025-07-10 18:00
2875
Week's Top Stories
Most Reposted
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 301 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 294 media titles]
2026-01-22 15:16
Infobip strengthens leadership to drive growth and innovation
[Picked up by 281 media titles]
2026-01-16 11:00
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 279 media titles]
2026-01-20 15:40
Novo Holdings Invests in Surya Hospitals to Strengthen Access to High-Quality Women's and Children's Healthcare in India
[Picked up by 276 media titles]
2026-01-20 09:00
